Hepatitis C virus, an important risk factor for tuberculosis in immunocompromised: experience with kidney transplantation

Torres, Juan J.; Aguado, José María; Juan, Rafael San; Andrés, Amado; Sierra, Prado; López‐Medrano, Francisco; Morales, José

doi:10.1111/j.1432-2277.2008.00694.x

Cited by 51 publications

(36 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Risk factors of TB transmission to kidney transplant recipients are direct contact with a TB carrier [17], blood group AB [18], hepatitis C [19], and allograft dysfunction with creatininemia higher than 1.5 mg/dl [14,19].…”

Section: Discussionmentioning

confidence: 99%

Mycobacterium Tuberculosis Infection Following Kidney Transplantation

Boubaker¹,

Abderrahim²,

Abdallah³

et al. 2013

AJIDM

View full text Add to dashboard Cite

Introduction and Aims. Post-transplant tuberculosis (TB) is a problem in successful long-term outcome of renal transplantation recipients. Our objective was to describe the pattern and risk factors of TB infection and the prognosis in our transplant recipients. Patients and Methods. This study was a retrospective review of the records of 491 renal transplant recipients in our hospital during the period from January 1986 to December 2009. The demographic data, transplant characteristics, clinical manifestations, diagnostic criteria, treatment protocol, and long-term outcome of this cohort of patients were analyzed. Results. 16 patients (3,2%) developed post-transplant TB with a mean age of 32,5 ± 12,7 (range: 13-60) years and a mean post-transplant period of 36,6months (range: 12,3 months-15,9 years). The forms of the diseases were pulmonary in 10/16 (62,6%), disseminated in 3/16 (18,7%), and extrapulmonary in 3/16 (18,7%). Graft dysfunction was observed in 7 cases (43,7%) with tissue-proof acute rejection in 3 cases and loss of the graft in 4 cases. Hepatotoxicity developed in 3 patients (18,7%) during treatment. Recurrences were observed in 4 cases after early stop of treatment. Two patients (12.5%) died. Conclusion. Extra pulmonary and disseminated tuberculosis were observed in third of our patients. More than 9months of treatment may be necessary to prevent recurrence.

show abstract

Section: Discussionmentioning

confidence: 99%

Mycobacterium Tuberculosis Infection Following Kidney Transplantation

Boubaker¹,

Abderrahim²,

Abdallah³

et al. 2013

AJIDM

View full text Add to dashboard Cite

show abstract

“…Research has identified a significant relationship between development of tuberculosis and presence of HCV infection in renal transplant recipients [64] , but it is not clear why HCV-positive recipients are more susceptible to this infection. Immunosuppression and diabetes are two possible explanations [63] .…”

Section: After Kt: Infectionsmentioning

confidence: 99%

Hepatitis C infection in hemodialysis patients: A review

Etık

Öcal

Boyacioglu

2015

WJH

View full text Add to dashboard Cite

Hepatitis C virus (HCV)-related liver disease is a significant cause of morbidity and mortality in patients with end-stage renal disease (ESRD) who is treated with dialysis or kidney transplantation (KT). The survival rate for HCV-infected renal transplant recipients is better than that for HCV-infected hemodialysis patients on transplant waiting lists. Early diagnosis and treatment HCV infection prior to KT prevents complications posttransplantation and reduces mortality. In addition to screening for anti-HCV antibodies and detecting HCV RNA, percutaneous liver biopsy is particularly valuable for assessing the stage of liver damage in HCV-infected patients, because the stage of fibrosis is important determining optimal treatment for HCV. Studies have been demonstrated that with conventional interferon (IFN) monotherapy or pegylated IFN monotherapy are similar efficacy and safety in HCV-infected hemodialysis patients. Sustained viral responses (SVRs) with these monotherapies have ranged approximately 30% to 40%. Limited reports support the use of IFN and ribavirin combination therapy as antiviral treatment for ESRD patients or patients on hemodialysis. Ribavirin can be started at low dose and careful monitoring for side effects. Patients that show SVR after treatment are strong candidates for KT. It is also generally accepted that ESRD patients with decompensated cirrhosis and portal hypertension should be referred to the liver transplant team for consideration of combined liver-KT.

show abstract

“…La principal dificultad para obtener datos precisos está dada por la calidad de los estudios donde la mayoría son retrospectivos y series de casos. Además, la información disponible se refiere fundamentalmente a trasplante renal y por tanto, no es necesariamente aplicable a los receptores de otros trasplantes [8][9][10] . Dentro de los factores de riesgo descritos para el desarrollo de TBC están la terapia con OKT3 o anticuerpos anti-linfocitarios 6 , diabetes mellitus, enfermedad hepática crónica, co-infecciones (CMV, micosis profunda, neumonía por Pneumocystis jiroveci y Nocardia sp) 11 , edad avanzada y el uso de ciclosporina.…”

Section: Epidemiologíaunclassified

Profilaxis de tuberculosis en niños y adultos sometidos a trasplante de órganos sólidos y precursores hematopoyéticos

Lafourcade

2012

Rev. chil. infectol.

View full text Add to dashboard Cite

SuplementoProfilaxis de tuberculosis en niños y adultos sometidos a trasplante de órganos sólidos y precursores hematopoyéticos Mónica LafourcadeProphylaxis against tuberculosis in pediatric and adult patients undergoing solid organ and hematopoietic stem cells transplantationRecipients of SOT and HSCT constitute a risk group for becoming ill with tuberculosis (TB). The prevalence of active TB in patients undergoing TOS is higher than in patients undergoing HSCT, probably for the shortest period of immunosuppression of the latter. Most TB cases occur in transplant patients by reactivation of latent infection after immunosuppression, which occurs most often within the first year post-transplant, causing graft loss and in some cases death. Relevant variables to assess the risk of TB infection in a transplant recipient are the medical history of donor and recipient, images, microbiology and tuberculin tests and interferon gamma levels. PPD is routinely performed in the donor and in the recipient before transplantation. If PPD is > 5 mm in the recipient or > 10 mm in the donor, it is neccesary to exclude active TB (pulmonary and renal) (A2). It is recommended chemoprophylaxis in recipients PPD (+) and in recipients with recent seroconversion (B3), if the donor has a history of untreated TB, there was contact to someone with active TB (B3), the radiological imeges are suspect (A2) and interferon gamma release assays is (+) (B2). The selected drug is isoniazid (C3).

show abstract

Hepatitis C virus, an important risk factor for tuberculosis in immunocompromised: experience with kidney transplantation

Cited by 51 publications

References 16 publications

Mycobacterium Tuberculosis Infection Following Kidney Transplantation

Mycobacterium Tuberculosis Infection Following Kidney Transplantation

Hepatitis C infection in hemodialysis patients: A review

Profilaxis de tuberculosis en niños y adultos sometidos a trasplante de órganos sólidos y precursores hematopoyéticos

Contact Info

Product

Resources

About